Suppr超能文献

用 rAAVrh74.MHCK7.GALGT2 对金毛寻回猎犬肌营养不良症(GRMD)犬进行短期治疗可诱导肌肉糖基化和抗肌萎缩蛋白表达,但对肌肉力量没有显著影响。

Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength.

机构信息

Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, United States of America.

Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, United States of America.

出版信息

PLoS One. 2021 Mar 26;16(3):e0248721. doi: 10.1371/journal.pone.0248721. eCollection 2021.

Abstract

We have examined the effects of intravenous (IV) delivery of rAAVrh74.MHCK7.GALGT2 in the golden retriever muscular dystrophy (GRMD) model of Duchenne Muscular Dystrophy (DMD). After baseline testing, GRMD dogs were treated at 3 months of age and reassessed at 6 months. This 3-6 month age range is a period of rapid disease progression, thus offering a relatively short window to establish treatment efficacy. Measures analyzed included muscle AAV transduction, GALGT2 transgene expression, GALGT2-induced glycosylation, muscle pathology, and muscle function. A total of five dogs were treated, 4 at 2x1014vg/kg and one at 6x1014vgkg. The 2x1014vg/kg dose led to transduction of regions of the heart with 1-3 vector genomes (vg) per nucleus, while most skeletal muscles were transduced with 0.25-0.5vg/nucleus. GALGT2-induced glycosylation paralleled levels of myofiber vg transduction, with about 90% of cardiomyocytes having increased glycosylation versus 20-35% of all myofibers across the skeletal muscles tested. Conclusions from phenotypic testing were limited by the small number of dogs. Treated dogs had less pronounced fibrosis and overall lesion severity when compared to control groups, but surprisingly no significant changes in limb muscle function measures. GALGT2-treated skeletal muscle and heart had elevated levels of utrophin protein expression and GALGT2-induced expression of glycosylated α dystroglycan, providing further evidence of a treatment effect. Serum chemistry, hematology, and cardiac function measures were largely unchanged by treatment. Cumulatively, these data show that short-term intravenous treatment of GRMD dogs with rAAVrh74.MHCK7.GALGT2 at high doses can induce muscle glycosylation and utrophin expression and may be safe over a short 3-month interval, but that such treatments had only modest effects on muscle pathology and did not significantly improve muscle strength.

摘要

我们研究了静脉(IV)注射 rAAVrh74.MHCK7.GALGT2 在杜氏肌营养不良症(DMD)金猎犬模型中的效果。在基线测试后,GRMD 犬在 3 个月大时接受治疗,并在 6 个月时重新评估。这个 3-6 个月的年龄范围是疾病快速进展的时期,因此提供了一个相对较短的时间窗口来建立治疗效果。分析的指标包括肌肉 AAV 转导、GALGT2 转基因表达、GALGT2 诱导的糖基化、肌肉病理学和肌肉功能。总共治疗了 5 只狗,4 只狗的剂量为 2x1014vg/kg,1 只狗的剂量为 6x1014vg/kg。2x1014vg/kg 的剂量导致心脏区域的每个核有 1-3 个载体基因组(vg)的转导,而大多数骨骼肌的转导则为每个核 0.25-0.5vg。GALGT2 诱导的糖基化与肌纤维 vg 转导水平平行,与对照组相比,约 90%的心肌细胞糖基化增加,而测试的骨骼肌中所有肌纤维的糖基化比例为 20-35%。由于狗的数量较少,表型测试的结论受到限制。与对照组相比,接受治疗的狗的纤维化和整体病变严重程度较轻,但令人惊讶的是,四肢肌肉功能测量没有明显变化。GALGT2 治疗的骨骼肌和心脏中,肌联蛋白蛋白表达和 GALGT2 诱导的糖基化α-肌营养不良蛋白表达水平升高,进一步证明了治疗效果。血清化学、血液学和心脏功能测量值在治疗后基本不变。总的来说,这些数据表明,高剂量静脉内 rAAVrh74.MHCK7.GALGT2 短期治疗 GRMD 犬可以诱导肌肉糖基化和肌联蛋白表达,并且在 3 个月的短时间内可能是安全的,但这种治疗对肌肉病理学的影响只有轻微,并没有显著改善肌肉力量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8719/7997012/26041c20774b/pone.0248721.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验